Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
2001
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
1998
Monocyte recruitment during infection and inflammation
2011 Standout
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Neutrophils at work
2014 Standout
The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis
2008
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Drug penetration in solid tumours
2006 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Initiation and regulation of T-cell responses in tuberculosis
2011
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials
2001
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens
2001
The role of IL-10 in immune regulation during M. tuberculosis infection
2011
Lipids, apoptosis, and cross-presentation: links in the chain of host defense against Mycobacterium tuberculosis
2011
Paclitaxel (Taxol)
1995 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer
2000
The immunological life cycle of tuberculosis
2012
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
2001 Standout
Second line chemotherapy for NSCLC: establishing a gold standard
2002
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
2000
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Early T‐cell responses in tuberculosis immunity
2008
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Enhanced protection to Mycobacterium tuberculosis infection in IL‐10‐deficient mice is accompanied by early and enhanced Th1 responses in the lung
2010
Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome
2015 StandoutNobel
High interstitial fluid pressure — an obstacle in cancer therapy
2004 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
1996
Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial
1999
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
1997
New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the seventh world conference on lung cancer
1995
Neuroblastoma
2007 Standout
Microtubules as a target for anticancer drugs
2004 Standout
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
2000
Regulation of type I interferon responses
2013 Standout
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling
2018 StandoutNobel
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Delivering nanomedicine to solid tumors
2010 Standout
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma
2001
Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
1999
Anemia of Chronic Disease
2005 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Cancer of the Ovary
2004 Standout
Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis
2015
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis
2019 StandoutNobel
Macrophage Polarization
2016 Standout
Immunology studies in non‐human primate models of tuberculosis
2015
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Lung Neutrophils Facilitate Activation of Naive Antigen-Specific CD4+ T Cells during Mycobacterium tuberculosis Infection
2011
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Blockade of IL-10 Signaling during Bacillus Calmette-Guérin Vaccination Enhances and Sustains Th1, Th17, and Innate Lymphoid IFN-γ and IL-17 Responses and Increases Protection to Mycobacterium tuberculosis Infection
2012
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
The Immune Response in Tuberculosis
2013 Standout
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.
1999
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
2000
Cardiotoxicity of Cancer Therapy
2005
Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial
1999
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis
2010
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
2001
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Cell-Mediated Immune Responses in Tuberculosis
2009 Standout
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
Works of Mark Calayag being referenced
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
1994
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
1995
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors.
1995
ESAT-6-specific CD4 T cell responses to aerosolMycobacterium tuberculosisinfection are initiated in the mediastinal lymph nodes
2008